Pharming on track for $10m milestone as it completes clinical part of US Ruconest trial
This article was originally published in Scrip
Executive Summary
Pharming Group has announced that it has completed the clinical part of its US pivotal Phase III trial (Study 1310) evaluating Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedoema in patients with hereditary angioedoema (HAE).